PE20140968A1 - Derivados de benzamida sustituida - Google Patents

Derivados de benzamida sustituida

Info

Publication number
PE20140968A1
PE20140968A1 PE2013002778A PE2013002778A PE20140968A1 PE 20140968 A1 PE20140968 A1 PE 20140968A1 PE 2013002778 A PE2013002778 A PE 2013002778A PE 2013002778 A PE2013002778 A PE 2013002778A PE 20140968 A1 PE20140968 A1 PE 20140968A1
Authority
PE
Peru
Prior art keywords
phenyl
fluor
cyane
urea
benzamide derivatives
Prior art date
Application number
PE2013002778A
Other languages
English (en)
Inventor
Guido Galley
Roger Norcross
Philippe Pflieger
Rene Trussardi
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20140968A1 publication Critical patent/PE20140968A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

SE REFIERE A UN COMPUESTO DE LA FORMULA (I), EN LA QUE R1 ES HIDROGENO, HALOGENO, CIANO, ENTRE OTROS; n ES EL NUMERO 1, 2; R2 ES HALOGENO, CIANO, ENTRE OTROS; R3 ES H; X ES UN ENLACE, -NR�-, -CH2NH-, -CHR�-; R� ES HIDROGENO, ALQUILO C1-C7; Z ES UN ENLACE, -CH2- , -O-; AR ES FENILO, HETEROARILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 1-(3-CIANO-FENIL)-3-((R) -2-FLUOR-4-MORFOLIN-2-IL-FENIL-UREA, 1-(3-CIANO-FENIL) -3-((S)-2-FLUOR-4-MORFOLIN-2-IL-FENIL)-UREA, 1-(3-CIANO-5-FLUOR-FENIL)-3-((S)-2-FLUOR-4-MORFOLIN-2-IL-FENIL)- UREA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA, SIENDO UTIL EN EL TRATAMIENTO DE LA DEPRESION, LOS TRASTORNOS DE ANSIEDAD, ENTRE OTROS.
PE2013002778A 2011-06-10 2012-06-06 Derivados de benzamida sustituida PE20140968A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11169441 2011-06-10

Publications (1)

Publication Number Publication Date
PE20140968A1 true PE20140968A1 (es) 2014-08-06

Family

ID=46298391

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002778A PE20140968A1 (es) 2011-06-10 2012-06-06 Derivados de benzamida sustituida

Country Status (32)

Country Link
US (1) US9029370B2 (es)
EP (1) EP2718271B1 (es)
JP (1) JP5788087B2 (es)
KR (1) KR101574906B1 (es)
CN (1) CN103596937B (es)
AR (1) AR086880A1 (es)
AU (1) AU2012266462B2 (es)
BR (1) BR112013030698B1 (es)
CA (1) CA2834675C (es)
CL (1) CL2013003485A1 (es)
CO (1) CO6811866A2 (es)
CY (1) CY1116769T1 (es)
DK (1) DK2718271T3 (es)
EA (1) EA022376B1 (es)
EC (1) ECSP13013073A (es)
ES (1) ES2546529T3 (es)
HK (1) HK1192562A1 (es)
HR (1) HRP20151201T1 (es)
IL (1) IL229335A (es)
MA (1) MA35194B1 (es)
MX (1) MX354410B (es)
MY (1) MY162461A (es)
PE (1) PE20140968A1 (es)
PL (1) PL2718271T3 (es)
PT (1) PT2718271E (es)
RS (1) RS54415B1 (es)
SG (1) SG194840A1 (es)
SI (1) SI2718271T1 (es)
TW (1) TWI445701B (es)
UA (1) UA110388C2 (es)
WO (1) WO2012168265A1 (es)
ZA (1) ZA201308401B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9073911B2 (en) 2011-06-09 2015-07-07 Hoffmann-La Roche Inc. Pyrazole derivatives
CA2856204A1 (en) * 2012-01-12 2013-07-18 F. Hoffmann-La Roche Ag Heterocyclic derivatives as trace amine associated receptors (taars)
RS56747B1 (sr) * 2012-09-14 2018-03-30 Hoffmann La Roche Pirazol derivati karboksamida kao taar modulatori za upotrebu u lečenju nekoliko poremećaja, kao što su depresija, dijabetes i parkinsonova bolest
BR112015001771B1 (pt) * 2012-09-17 2022-08-16 F. Hoffmann-La Roche Ag Derivados de carboxamida de triazol, seu uso e composição farmacêutica que os compreende
MX2015005721A (es) * 2012-11-07 2015-09-08 Hoffmann La Roche Derivados de pirazina.
WO2015165085A1 (en) * 2014-04-30 2015-11-05 F.Hoffmann-La Roche Ag Morpholin-pyridine derivatives
ES2674800T3 (es) * 2014-05-28 2018-07-04 F. Hoffmann-La Roche Ag Derivados de 5-oxa-2-azabiciclo[2.2.2]octan-4-ilo y 5-oxa-2-azabiciclo[2.2.1]heptan-4-ilo como moduladores de TAAR1
CN104478798B (zh) * 2014-12-18 2017-01-18 武汉华纳联合药业有限公司 N‑氨基烷基磺酰基‑3‑吡啶甲酰胺衍生物及其在制备治疗心脑血管病药物中的应用
MA43706B1 (fr) 2016-03-17 2020-09-30 Hoffmann La Roche Dérivé de 5-éthyl-4-méthyl-pyrazole-3-carboxamide ayant une activité en tant qu'agoniste de taar
CN115515940A (zh) * 2020-02-28 2022-12-23 德州大学系统董事会 用于治疗疾病的受体相互作用蛋白激酶i的抑制剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9425211D0 (en) 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
GB9520150D0 (en) 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
PL341009A1 (en) 1997-12-04 2001-03-12 Allergan Sales Substitute derivatives of imidazole exhibiting agonist-like activity in respect to adrenergic alpha 2b or 2b/2c receptors
US6841684B2 (en) 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
AR050865A1 (es) * 2004-09-09 2006-11-29 Sanofi Aventis Derivados de 2- morfolino-4-pirimidona
WO2008026046A1 (en) 2006-08-30 2008-03-06 Pfizer Products Inc. Morpholine d3 dopamine antagonists
CL2007003874A1 (es) * 2007-01-03 2008-05-16 Boehringer Ingelheim Int Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio
WO2008092930A1 (en) 2007-02-02 2008-08-07 Novartis Ag Chromene s1p1 receptor antagonist
CN101616902B (zh) 2007-02-15 2013-03-27 弗·哈夫曼-拉罗切有限公司 作为taar1配体的2-氨基*唑啉类化合物
BRPI0815038A2 (pt) 2007-08-02 2015-03-17 Hoffmann La Roche Uso de derivados de benzamida para o tratamento de transtornos do cns
AR077969A1 (es) 2009-08-31 2011-10-05 Abbott Healthcare Products Bv Derivados de (tio)morfolina comomoduladores de s1p
HUE043522T2 (hu) 2009-09-04 2019-08-28 Biogen Ma Inc Bruton tirozinkináz inhibitorok
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US9132136B2 (en) * 2010-08-02 2015-09-15 Hoffmann-La Roche Inc. Pharmaceutical combination
US9073911B2 (en) 2011-06-09 2015-07-07 Hoffmann-La Roche Inc. Pyrazole derivatives

Also Published As

Publication number Publication date
ECSP13013073A (es) 2014-01-31
US9029370B2 (en) 2015-05-12
CO6811866A2 (es) 2013-12-16
AU2012266462A1 (en) 2013-10-31
HK1192562A1 (zh) 2014-08-22
EP2718271A1 (en) 2014-04-16
TWI445701B (zh) 2014-07-21
ES2546529T3 (es) 2015-09-24
EP2718271B1 (en) 2015-08-12
HRP20151201T1 (hr) 2015-12-04
EA022376B1 (ru) 2015-12-30
SI2718271T1 (sl) 2015-11-30
BR112013030698A2 (pt) 2016-12-06
KR101574906B1 (ko) 2015-12-04
DK2718271T3 (en) 2015-08-24
AR086880A1 (es) 2014-01-29
BR112013030698B1 (pt) 2022-05-31
KR20140028102A (ko) 2014-03-07
ZA201308401B (en) 2014-08-27
IL229335A (en) 2016-11-30
CL2013003485A1 (es) 2014-09-12
TW201307308A (zh) 2013-02-16
RS54415B1 (en) 2016-04-28
CY1116769T1 (el) 2017-03-15
MX354410B (es) 2018-03-05
SG194840A1 (en) 2013-12-30
CN103596937B (zh) 2016-06-29
MX2013014371A (es) 2014-01-31
EA201391815A1 (ru) 2014-04-30
UA110388C2 (en) 2015-12-25
JP2014516067A (ja) 2014-07-07
US20120316165A1 (en) 2012-12-13
PL2718271T3 (pl) 2016-01-29
MA35194B1 (fr) 2014-06-02
CN103596937A (zh) 2014-02-19
CA2834675C (en) 2019-09-03
NZ616820A (en) 2015-11-27
CA2834675A1 (en) 2012-12-13
AU2012266462B2 (en) 2016-09-22
WO2012168265A1 (en) 2012-12-13
JP5788087B2 (ja) 2015-09-30
IL229335A0 (en) 2014-01-30
MY162461A (en) 2017-06-15
PT2718271E (pt) 2015-10-29

Similar Documents

Publication Publication Date Title
PE20140968A1 (es) Derivados de benzamida sustituida
PE20142282A1 (es) Nuevos derivados de aril-quinolina
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
PE20140934A1 (es) Derivados de pirazol
EA200901379A1 (ru) Производные никотиновой кислоты как модуляторы метаботропных глутаматных рецепторов 5 подтипа
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
ECSP10010272A (es) Derivados bis-(sulfonilamino) para uso en terapia
PE20130311A1 (es) Composiciones y metodos para modular la via de senalizacion de wnt
PE20141996A1 (es) Compuestos con actividad nematicida
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
AR075583A1 (es) Derivados de isoxazol/o-piridina con eslabon etilo o etenilo
UY29184A1 (es) Derivados de sulfonilbencimidazol
WO2007022934A3 (en) Azabicyclo (3, 1, 0) hexan derivatives useful as modulators of dopamine d3 receptors
PE20091425A1 (es) Derivados de aminotiazol
CO6280476A2 (es) Derivados de alcanos azabiciclicos sustituidos con biarilo como moduladores de la actividad de los receptores nicotinicos de acetilcolina
UY30897A1 (es) Derivados de pentafluorotiobenzamidoacetonitrilo, composiciones conteniéndolos y aplicaciones
AR078756A1 (es) Moduladores alostericos positivos (map)
UA109525C2 (xx) Алкіламідна сполука і її застосування
AR074817A1 (es) Dihidropiridona-amidas como moduladores de p2x7
RS51661B (en) NEW DIOSMETHINE DERIVATIVES, THE PROCEDURE FOR THEIR MAKING AND THE PHARMACEUTICAL MIXTURES CONTAINING THEM
AR071925A1 (es) Malonamidas como antagonistas de orexina
AR087494A1 (es) Derivados de isoxazolina como compuestos insecticidas
ECSP088257A (es) Derivados de amida
AR074353A1 (es) Acidos naftalen-2-il-aceticos sustituidos, composiciones farmaceuticas que los contienen, y uso de los mismos en el tratamiento de enfermedades alergicas,tales como rinitis, asma y dermatititis atopica.

Legal Events

Date Code Title Description
FG Grant, registration